CE mark of approval for cataract laser system

Article

The CE mark of approval has been given to OptiMedica's Catalys Precision Laser System.

The CE mark of approval has been given to OptiMedica's Catalys Precision Laser System.

The Catalys has been approved to deliver capsulotomy and lens fragmentation. OptiMedica are currently awaiting approval for corneal incisions - anticipated in the near future.

The laser system incorporates the use of a femtosecond laser and optical coherence tomography (OCT) imaging. The optical path to the patient's eye is optimized to guarantee stable system-patient attachment due to the Liquid Optics Interface. Catalys also offers a proprietary Integral Guidance system that ensures safe and precise femtosecond laser pulses during surgery. The graphical user interface is simple to use and reduces patient time under the dock.

Dr William Culbertson, Professor of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, USA, said, "The system's CE mark of approval is a tremendous milestone that rewards years of intense collaboration to deliver the greatest precision and best experience for both surgeon and patient."

Mark J. Forchette, OptiMedica's president and chief executive officer, added, "We are excited to enter this new stage in OptiMedica's history, and we look forward to introducing Catalys to markets around the world in the very near future."

The first shipment of the Catalys will be introduced to Europe late this year.

If you would like to read more on this system please click here for an article by Dr Jonathan Talamo that was published in April's print issue of OTEurope on his experiences with the system and his thoughts on femtosecond laser cataract surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.